Avanir Pharmaceuticals Inc (NASDAQ:AVNR) is all set on the right path after the successful Phase II clinical trial results of AVP-923. Piper Jaffray, stock analysis firm, upgraded the rating of Avanir Pharmaceuticals to a “positive” with a target price of $17. The shares of Avanir Pharmaceuticals nearly doubled after the positive test result announcement. Another…
Avanir Pharmaceuticals Inc (AVNR)’s Shares Touch New Heights on Successful Trial Results
The shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) have soared after successful Phase II clinical trial results of AVP-923, which was successful in reducing the agitation of patients suffering from Alzheimer. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) share prices soared by $5.75 and closed after a hike of 85.31 percent. According to the official press release from Avanir…